Avail Bio

10:30 AM - 10:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Immunotherapy is revolutionizing cancer treatment. By activating a patient’s own immune system to fight off their tumor, clinicians are now saving or extending the lives of patients with advanced-stage and metastatic cancer. Yet, in spite of its major health impact, immunotherapy has also brought new growing pains. These include (a) low response rates and (b) risk of severe autoimmune side effects.

To provide a better immunotherapy roadmap for patients, clinicians, and biopharma, Avail is leveraging a new genomic technology to profile the immune system of a cancer patient. Avail's blood-based biomarker discovery platform is designed to better estimate the likelihood of clinical benefit for immunotherapy, and is based on years of research at UCSF. With support from Illumina Accelerator and institutional venture capital, Avail is collaborating with genomic scientists, industry leaders, and oncologists around the country to build better solutions for patients, practitioners, and pharma.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
CDx
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO, Founder
Avail Bio